Iterion Therapeutics is developing novel cancer therapeutics targeting nuclear β-catenin, a historically “undruggable” oncology target implicated in cell proliferation.
Employees: 1-10
Total raised: $17M
Founded date: 2010
Investors 2
| Date | Name | Website |
| - | Lumira Ven... | lumiravent... |
| - | GOOSE Capi... | goose.capi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.02.2021 | Series B | $17M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 20.02.2024 | Iterion Therapeutics Announces First Patient Dosed in Phase ... | Iterion Therapeutics, an oncology-focused biopharmaceutical company developing small molecule inhibi... | lumiravent... |
| 16.02.2021 | Iterion Therapeutics Secures $17 Million to Advance Developm... | HOUSTON, Feb. 16, 2021 /PRNewswire/ — Iterion Therapeutics, Inc. ("Iterion"), a venture-ba... | oaoa.com/l... |
| 16.02.2021 | Iterion Therapeutics Secures $17 Million to Advance Developm... | Series B financing to support ongoing Phase 1/2a clinical trial of Tegavivint in desmoid tumors and ... | lumiravent... |
| 16.02.2021 | Iterion Therapeutics Secures $17 Million to Advance Developm... | prnewswire... | |
| 16.02.2021 | Iterion Therapeutics Lands $17M Series B | HOUSTON, TX, Iterion Therapeutics has raised $17 million in a Series B financing. >> Click ... | vcnewsdail... |